
    
      Patients with newly diagnosed Glioblastoma Multiforme Tumours, once consented to the study,
      would undergo standard treatment of radiotherapy plus chemotherapy (TMZ) with DCA in pill
      form (twice a day) during the radiation phase of the study and then with TMZ for six months
      after. Other elements of the clinical trial include pharmacokinetics and MGMT genetic
      testing.
    
  